GH1 and acromegaly: The percentage of patients achieving the composite endpoint of both GH and IGF-1 control after 1 year of treatment in prospective studies of patients with previously untreated acromegaly was 17–27 % with octreotide LAR [16–18] and 33–54 % with lanreotide Autogel [22, 33].